Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
42
PTGX Quote, Financials, Valuation and Earnings
Last price:
$39.25
Seasonality move
:
28.98%
Day range:
$38.90 - $40.44
52-week range:
$21.43 - $48.89
Dividend yield:
0%
P/E ratio:
14.77x
P/S ratio:
7.50x
P/B ratio:
4.40x
Volume:
249.3K
Avg. volume:
834.8K
1-year change:
76.71%
Market cap:
$2.3B
Revenue:
$60M
EPS (TTM):
$2.66
Analysts' Opinion
-
Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Protagonist Therapeutics has an estimated upside of 46.31% from its current price of $39.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $39.30.
Fair Value
-
According to the consensus of 3 analysts, Protagonist Therapeutics has 46.31% upside to fair value with a price target of -- per share.
PTGX vs. S&P 500
-
Over the past 5 trading days, Protagonist Therapeutics has underperformed the S&P 500 by -6.18% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Protagonist Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protagonist Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Protagonist Therapeutics reported revenues of $4.7M.
Earnings Growth
-
Protagonist Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Protagonist Therapeutics reported earnings per share of -$0.54.
Enterprise value:
1.9B
EV / Invested capital:
3.52x
Price / LTM sales:
7.50x
EV / EBIT:
12.56x
EV / Revenue:
5.79x
PEG ratio (5yr expected):
--
EV / Free cash flow:
8.17x
Price / Operating cash flow:
10.59x
Enterprise value / EBITDA:
12.30x
Gross Profit (TTM):
--
Return On Assets:
33.69%
Net Income Margin (TTM):
52.77%
Return On Equity:
37.59%
Return On Invested Capital:
37.59%
Operating Margin:
-886.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $323.8M | -- | $4.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$131.9M | -$153.2M | $149.1M | -$38.3M | -$41.5M | |
| EBITDA | -$128.5M | -$149.9M | $152.3M | -$37.5M | -$40.8M | |
| Diluted EPS | -$2.68 | -$2.62 | $2.66 | -$0.58 | -$0.54 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $204.2M | $327.7M | $276.6M | $324.9M | $476.8M | |
| Total Assets | $217.3M | $373.2M | $282.2M | $330M | $603.9M | |
| Current Liabilities | $38.6M | $39.2M | $36.8M | $27.9M | $44.6M | |
| Total Liabilities | $47.7M | $43.5M | $38.6M | $27.9M | $71.9M | |
| Total Equity | $169.6M | $329.7M | $243.6M | $302.1M | $531.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$103.4M | -$118.8M | $230.3M | -$26.6M | -$27.9M | |
| Cash From Investing | $115.4M | $26M | -$352M | -$13.6M | -$208.7M | |
| Cash From Financing | $20.5M | $170.5M | $22.3M | $35.3M | $12.1M | |
| Free Cash Flow | -$104.4M | -$119.5M | $229.2M | -$27M | -$28.6M | |
PTGX
Sector
Market Cap
$2.3B
$46.1M
Price % of 52-Week High
80.39%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
76.71%
-30.52%
Beta (5-Year)
2.178
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$40.40
200-day SMA
Buy
Level
$37.11
Bollinger Bands (100)
Sell
Level
40.3 - 46.26
Chaikin Money Flow
Buy
Level
68.3M
20-day SMA
Sell
Level
$41.45
Relative Strength Index (RSI14)
Sell
Level
41.13
ADX Line
Buy
Level
19.19
Williams %R
Buy
Level
-84.4595
50-day SMA
Sell
Level
$43.78
MACD (12, 26)
Sell
Level
-0.99
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
155.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (35.3373)
Buy
CA Score
(Annual)
Level (0.1079)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.5478)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Stock Forecast FAQ
In the current month, PTGX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PTGX average analyst price target in the past 3 months is --.
-
Where Will Protagonist Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protagonist Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Protagonist Therapeutics?
Analysts are divided on their view about Protagonist Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protagonist Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Protagonist Therapeutics's Price Target?
The price target for Protagonist Therapeutics over the next 1-year time period is forecast to be -- according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PTGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protagonist Therapeutics is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTGX?
You can purchase shares of Protagonist Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protagonist Therapeutics shares.
-
What Is The Protagonist Therapeutics Share Price Today?
Protagonist Therapeutics was last trading at $39.25 per share. This represents the most recent stock quote for Protagonist Therapeutics. Yesterday, Protagonist Therapeutics closed at $39.30 per share.
-
How To Buy Protagonist Therapeutics Stock Online?
In order to purchase Protagonist Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
